From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer– insights from the national cancer institute
Abstract Background Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior and limited treatment options, primarily due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TROP-2, a transmembr...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2025-06-01
|
| Rangatū: | BMC Cancer |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12885-025-14402-7 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|